Inspire Medical Systems, Inc. (INSP)

Inspire Medical Systems, Inc.'s Q·Score is 8/10 (Bullish), reflecting its current fundamentals, analyst data, and valuation metrics. Clean balance sheet with low leverage (0.0× debt-to-equity). Key area to monitor: cautious analyst consensus — few Buy ratings. This is an informational data summary only and does not constitute financial advice. Always do your own research before making any investment decision.

The consensus price target for INSP is $72.25, based on ratings from 12 Wall Street analysts. This is 27.4% above the current price of $56.70. Price targets are forward-looking estimates and not guarantees of future performance.

Inspire Medical Systems, Inc. (INSP) scores favorably on valuation metrics relative to sector peers and analyst targets. Its forward P/E ratio stands at 21.9×. The consensus analyst price target of $72.25 is 27% above the current price.

Inspire Medical Systems, Inc. is scheduled to report earnings tomorrow (May 4, 2026).

Inspire Medical Systems, Inc. has a net profit margin of 15.9%, which is solid for most industries. Its gross margin stands at 85.4%, indicating a high-margin business model.

Inspire Medical Systems, Inc. is reporting solid revenue growth of 12.2% year-over-year. Earnings are also growing at 308.4%, indicating improving profitability.

Inspire Medical Systems, Inc. has a debt-to-equity ratio of 0.04×, reflecting a very low debt-to-equity ratio, signalling a conservatively financed balance sheet. Its current ratio is 6.08×, indicating comfortable short-term liquidity.